Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | -0.69% | 342.85 | 1.2% | $619.74m | |
| GILD | Gilead Sciences, Inc. | -0.75% | 72.37 | 0.9% | $506.86m | |
| CELG | Celgene Corporation | -0.45% | 89.96 | 1.2% | $494.15m | |
| AMGN | Amgen Inc. | -0.14% | 197.14 | 1.2% | $484.65m | |
| ILMN | Illumina, Inc. | 0.13% | 326.30 | 3.5% | $374.18m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.48% | 372.48 | 2.6% | $314.28m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.06% | 174.22 | 1.9% | $206.87m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.15% | 116.17 | 2.0% | $186.86m | |
| A | Agilent Technologies, Inc. | 0.11% | 64.73 | 1.5% | $159.45m | |
| SRPT | Sarepta Therapeutics, Inc. | -0.43% | 129.69 | 16.6% | $141.85m | |
| NKTR | Nektar Therapeutics | 0.43% | 60.29 | 5.6% | $126.83m | |
| BLUE | Bluebird Bio, Inc. | -0.29% | 157.55 | 14.6% | $121.23m | |
| EXAS | Exact Sciences Corporation | -0.85% | 48.43 | 25.3% | $117.82m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.12% | 98.87 | 4.4% | $116.23m | |
| INCY | Incyte Corporation | -0.39% | 68.53 | 2.5% | $111.30m |
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.